LDLR and atherosclerosis: PCSK9i are effective in lowering LDL-C levels and reducing the risk of ASCVD events by competitively inhibiting the binding of PCSK9 to the LDL receptors (LDLRs), thereby maintaining higher hepatic LDLR density and enhancing LDL-C clearance (Hummelgaard et al., 2023).